Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion

Table 1

Patient characteristics by treatment group.

	IVB combined with MLP; Group 1; (𝑛=9)	IVB only; Group 2; (𝑛=11)	𝑃 value
Age (years)	70.2±7.16	65.0±13.9	NS^a
Gender (male/female)	5/4	5/6	NS^b
Hypertension	5	6	NS^b
Baseline BCVA (logMAR)	0.57±0.34	0.53±0.34	NS^a
Baseline CST (𝜇m)	431.2±142.7	516.4±225.3	NS^a
Number of IVB during 12 months of follow-up	2.44±1.24	2.55±0.52	NS^a
Number of MLP during 12 months of follow-up	1.22±0.42	0	NA
Duration between onset of BRVO and first IVB (days)	17.7±4.5	19.8±5.7	NS^a
Duration between first IVB and second IVB (months)	3.3±0.7	3.6±1.1	NS^a
Follow-up (months)	17.8±3.1	14.5±5.5	NS^a

BCVA = best corrected visual acuity; CST = central subfield thickness; MLP = macular laser photocoagulation; IVB = intravitreal bevacizumab; logMAR VA = logarithm of the minimal angle of resolution visual acuity; NS = not significant; NA = not available; aMann-Whitney test; ^bchi-square test.